BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis of epilepsy.
Epilepsy is a serious neurological condition that impacts over 65M people around the world.
BioEP is a patented seizure risk score calculated from routine EEG recordings that can enable faster and more accurate diagnosis and prognosis of epilepsy.
Neuronostics is a collaborative organisation and welcomes enquiries from researchers, clinicians and commercial partners.
Neuronostics is a new company (founded 2018) developing a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.
Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.
We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.
20 May 2020 We’re delighted to announce that we have been awarded £50,000 from Innovate UK to develop an app to support the epilepsy community during the COVID-19 crisis. This funding will... [Read More]
18th May 2020 We’re delighted to announce that our Scientific Director – Dr Wessel Woldman – has recently secured a prestigious Emerging Leader Fellowship from Epilepsy Research UK . Epilepsy Research UK... [Read More]
27th April 2020 A paper published today in Scientific Reports documents the research underpinning Neuronostics’ technology. The R&D team in Neuronostics are building on these findings, which will enable diagnostic and prognostic... [Read More]